Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Solomon SR, Sizemore CA, Zhang X, Brown S, Holland HK, Morris LE, Solh M, Bashey A. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. Biol Blood Marrow Transplant 2016;22:1816-1822. [DOI: 10.1016/j.bbmt.2016.07.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 07/20/2016] [Indexed: 11/30/2022]

For:	Solomon SR, Sizemore CA, Zhang X, Brown S, Holland HK, Morris LE, Solh M, Bashey A. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. Biol Blood Marrow Transplant 2016;22:1816-1822. [DOI: 10.1016/j.bbmt.2016.07.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 07/20/2016] [Indexed: 11/30/2022]

Number

Cited by Other Article(s)

Wang Y, Lai C, Chen T, Gau J, Teng CJ. Haploidentical and matched unrelated donor allogeneic hematopoietic stem cell transplantation offer similar survival outcomes for acute leukemia. Cancer Rep (Hoboken) 2024;7:e2060. [PMID: 38600053 PMCID: PMC11006712 DOI: 10.1002/cnr2.2060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 03/02/2024] [Accepted: 03/24/2024] [Indexed: 04/12/2024] Open

Roman Diaz JL, Vazquez Martinez M, Khimani F. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches. Cancers (Basel) 2024;16:677. [PMID: 38339429 PMCID: PMC10854755 DOI: 10.3390/cancers16030677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 02/02/2024] [Accepted: 02/02/2024] [Indexed: 02/12/2024] Open

Pereira MP, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I. Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Transplant Cell Ther 2023;29:697.e1-697.e10. [PMID: 37579919 DOI: 10.1016/j.jtct.2023.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 07/28/2023] [Accepted: 08/08/2023] [Indexed: 08/16/2023]

Abstract

The choice between an older matched sibling donor (MSD) and a younger matched unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a subject of ongoing debate. In this single-center retrospective study of 377 patients who received peripheral blood stem cell (PBSC) transplants for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), we compared outcomes of 85 patients who received grafts from MSDs age >60 years and 292 patients who received grafts from MUDs age <30 years. Compared to recipients of MSD transplants, recipients of MUD transplants were younger and more likely to receive dual T cell depletion (TCD), a higher CD34+ cell dose, and a fresh graft. Recipients of MSD transplants were maintained on immunosuppressive therapy longer than those who received MUD grafts. We found no differences in overall survival, relapse-free survival, graft-versus-host disease (GVHD)-free and relapse-free survival, nonrelapse mortality, relapse, engraftment, graft failure, and acute GVHD between recipients of MSD grafts and recipients of MUD grafts. We report a higher 30-day incidence, but not 1-year incidence, of bloodstream infections among recipients of MUD transplants compared to subjects who received their grafts from a MSD. The incidence of moderate-severe chronic GVHD was higher in MSD graft recipients compared with MUD graft recipients in univariate analysis, but not in multivariate analysis. Although this difference could reflect the greater use of dual TCD, known to be associated with very low rates of chronic GVHD in MUD transplant recipients, the incidence of moderate-severe chronic GVHD was no different between MSD and MUD transplant recipients following propensity score matching, suggesting that other variables could be responsible. Taken together, our data suggest that in patients with AML or MDS who receive PBSC transplants, such factors as convenience, ease of access, and costs should be considered when selecting an older MSD over a younger MUD.

Collapse

Affiliation(s)

Mariana Pinto Pereira Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
Mats Remberger Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden
Carol Chen Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
Armin Gerbitz Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Dennis Dong Hwan Kim Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Rajat Kumar Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Wilson Lam Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Arjun Datt Law Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Jeffrey H Lipton Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Fotios V Michelis Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Igor Novitzky-Basso Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Auro Viswabandya Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Jonas Mattsson Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Ivan Pasic Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Collapse

Liberatore C, Di Ianni M. Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation. Int J Mol Sci 2023;24:15019. [PMID: 37834466 PMCID: PMC10573608 DOI: 10.3390/ijms241915019] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 10/05/2023] [Accepted: 10/07/2023] [Indexed: 10/15/2023] Open

Salamonowicz-Bodzioch M, Rosa M, Frączkiewicz J, Gorczyńska E, Gul K, Janeczko-Czarnecka M, Jarmoliński T, Kałwak K, Mielcarek-Siedziuk M, Olejnik I, Owoc-Lempach J, Panasiuk A, Gajek K, Rybka B, Ryczan-Krawczyk R, Ussowicz M. Fludarabine-Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia. J Clin Med 2021;10:jcm10194416. [PMID: 34640434 PMCID: PMC8509585 DOI: 10.3390/jcm10194416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/21/2021] [Accepted: 09/23/2021] [Indexed: 01/18/2023] Open

Affiliation(s)

Małgorzata Salamonowicz-Bodzioch Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.) Correspondence: ; Tel.: +48-71-7332700; Fax: +48-71-7332709
Monika Rosa Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Jowita Frączkiewicz Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Ewa Gorczyńska Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Katarzyna Gul Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Małgorzata Janeczko-Czarnecka Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Tomasz Jarmoliński Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Krzysztof Kałwak Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Monika Mielcarek-Siedziuk Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Igor Olejnik Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Joanna Owoc-Lempach Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Anna Panasiuk Department of Oncology, Hematolgy and Transplantology, University Hospital USK in Wroclaw, 50-556 Wroclaw, Poland;
Kornelia Gajek Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Blanka Rybka Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Renata Ryczan-Krawczyk Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)
Marek Ussowicz Department of Pediatric Oncology, Haematology and Bone Marrow Transplantation, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; (M.R.); (J.F.); (E.G.); (K.G.); (M.J.-C.); (T.J.); (K.K.); (M.M.-S.); (I.O.); (J.O.-L.); (K.G.); (B.R.); (R.R.-K.); (M.U.)

Collapse

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv 2021;4:3913-3925. [PMID: 32813874 DOI: 10.1182/bloodadvances.2020001648] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 07/06/2020] [Indexed: 01/19/2023] Open

Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther 2021;27:6-20. [PMID: 32966881 DOI: 10.1016/j.bbmt.2020.09.020] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 09/10/2020] [Indexed: 12/31/2022]

Affiliation(s)

Bhagirathbhai Dholaria Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Bipin N Savani Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Betty K Hamilton Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Betul Oran Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas
Hien D Liu Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida
Martin S Tallman Memorial Sloan Kettering Cancer Center, New York, New York
Stefan Octavian Ciurea Division of Hematology/Oncology, University of California, Irvine, California
Noa G Holtzman Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Gordon L Phillips Ii Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Steven M Devine National Marrow Donor Program and Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
Gabriel Mannis Department of Medicine, Division of Hematology, Stanford University, Stanford, California
Michael R Grunwald Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
Frederick Appelbaum Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington
Cesar Rodriguez Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Firas El Chaer Division of Hematology/Oncology, University of Virginia, Charlottesville, Virginia
Nina Shah Division of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
Shahrukh K Hashmi Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
Mohamed A Kharfan-Dabaja Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida
Zachariah DeFilipp Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts
Mahmoud Aljurf Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
AlFadel AlShaibani Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Yoshihiro Inamoto Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
Tania Jain Sidney Kimmel Cancer Center, John Hopkins Hospital, Baltimore, Maryland
Navneet Majhail Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Miguel-Angel Perales Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
Mohamad Mohty Saint Antoine Hospital, INSERM UMR 938, Université Pierre et Marie Curie, TC, Paris, France; EBMT Paris Study Office, Paris, France
Mehdi Hamadani Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Paul A Carpenter Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington
Arnon Nagler EBMT Paris Study Office, Paris, France; Chaim Sheba Medical Center, Tel Hashomer, Israel

Collapse

Dholaria B, Labopin M, Angelucci E, Tischer J, Arat M, Ciceri F, Gülbas Z, Ozdogu H, Sica S, Diez-Martin JL, Koc Y, Pavlu J, Socié G, Giebel S, Savani BN, Nagler A, Mohty M. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplant Cell Ther 2020;27:171.e1-171.e8. [PMID: 33830029 DOI: 10.1016/j.jtct.2020.10.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 10/13/2020] [Accepted: 10/14/2020] [Indexed: 01/09/2023]

Affiliation(s)

Bhagirathbhai Dholaria Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Myriam Labopin Saint Antoine Hospital, INSERM UMR 938 and EBMT Paris Study Office/CEREST-TC, Paris, France
Emanuele Angelucci Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Johanna Tischer Medical Clinic III, Klinikum Grosshadern, Munich, Germany
Mutlu Arat Florence Nightingale Sisli Hospital, Hematopoietic SCT Unit, Istanbul, Turkey
Fabio Ciceri Hematology and BMT, Ospedale San Raffaele, Milan, Italy
Zafer Gülbas Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey
Hakan Ozdogu Hematology Division, BMT Unit, Hematology Research Laboratory, Training & Medical, Baskent University Hospital, Adana, Turkey
Simona Sica Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
Jose Luis Diez-Martin Department of Hematology, Hospital GU Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Medicina, Madrid, Spain
Yener Koc Medicana International, Istanbul, Turkey
Jiri Pavlu Department of Haematology, Imperial College, Hammersmith Hospital, London, United Kingdom
Gerard Socié Department of Hematology-BMT, Hopital St Louis, Paris, France
Sebastian Giebel Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute Oncology Center, Gliwice, Poland
Bipin N Savani Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Arnon Nagler Division of Hematology, Chaim Sheba Medical Center, Tel HaShomer, Israel; Acute Leukemia Working Party Office, Hôpital Saint-Antoine, Paris, France
Mohamad Mohty Saint Antoine Hospital, INSERM UMR 938, Université Pierre et Marie Curie, Paris, France; European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France

Collapse

Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, Sica S, Meijer E, Ciceri F, Van Gorkom G, Kröger N, Martin H, Pioltelli P, Risitano A, Canaani J, Savani BN, Sanz J, Mohty M. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clin Cancer Res 2020;27:843-851. [PMID: 33148668 DOI: 10.1158/1078-0432.ccr-20-2809] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 08/31/2020] [Accepted: 10/30/2020] [Indexed: 11/16/2022]

Affiliation(s)

Arnon Nagler Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel.,EBMT ALWP office Hôpital Saint-Antoine, Paris, France
Myriam Labopin EBMT ALWP office Hôpital Saint-Antoine, Paris, France
Bhagirathbhai Dholaria Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Emanuele Angelucci Hematology and Transplant Center, IRCCS Ospedale Policlinico, San Martino, Genova, Italy
Boris Afanasyev Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva Memorial Research, St. Petersburg, Russian Federation
Jan J Cornelissen Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands
Simona Sica Istituto di Ematologia, Ematologia, Universita Cattolica S. Cuore, Rome, Italy
Ellen Meijer Department of Hematology (Br 250), VU University Medical Center, Amsterdam, the Netherlands
Fabio Ciceri Haematology and BMT, Ospedale San Raffaele s.r.l, Milano, Italy
Gwendolyn Van Gorkom Department of Internal Medicine, Hematology/Oncology, University Hospital Maastricht, Maastricht, the Netherlands
Nicolaus Kröger Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany
Hans Martin Hämatologie, Medizinische Onkologie, Goethe-Universitaet, Medizinische Klinik II, Frankfurt, Germany
Pietro Pioltelli Clinica Ematologica dell Universita Milano-Biocca, Ospedale San Gerardo, Monza, Italy
Antonio Risitano Division of Hematology, University of Napoli, Federico II Medical School, Napoli, Italy
Jonathan Canaani Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
Bipin N Savani Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Jaime Sanz Hematology Department, University Hospital La Fe, Valencia, Spain
Mohamad Mohty Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France

Collapse

Dholaria B, Labopin M, Angelucci E, Ciceri F, Diez-Martin JL, Bruno B, Sica S, Koc Y, Gülbas Z, Schmid C, Blaise D, Carella AM, Visani G, Savani BN, Nagler A, Mohty M. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. Am J Hematol 2020;95:1200-1208. [PMID: 32656791 DOI: 10.1002/ajh.25934] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 07/06/2020] [Accepted: 07/08/2020] [Indexed: 12/14/2022]

The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplant 2020;56:20-29. [PMID: 32561816 DOI: 10.1038/s41409-020-0974-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 06/01/2020] [Accepted: 06/09/2020] [Indexed: 11/08/2022]

Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia 2020;34:2766-2775. [DOI: 10.1038/s41375-020-0850-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2019] [Revised: 04/23/2020] [Accepted: 04/27/2020] [Indexed: 12/20/2022]

Grønvold B, Ali MM, Remberger M, Mattsson J, Egeland T, Lundin KU, Myhre AE, Abrahamsen IW, Heldal D, Dybedal I, Tjønnfjord GE, Fløisand Y, Gedde-Dahl T. HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55:1658-1661. [PMID: 32054997 DOI: 10.1038/s41409-020-0827-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 01/16/2020] [Accepted: 02/03/2020] [Indexed: 11/09/2022]

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica 2020;105:47-58. [PMID: 31537691 PMCID: PMC6939532 DOI: 10.3324/haematol.2019.219790] [Citation(s) in RCA: 48] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Accepted: 09/19/2019] [Indexed: 01/30/2023] Open

Affiliation(s)

Bhagirathbhai Dholaria Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
Bipin N Savani Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
Myriam Labopin Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France
Leo Luznik Department of Oncology Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Annalisa Ruggeri Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Stephan Mielke Department of Laboratory Medicine, CAST, Karolinska Institutet and University Hospital, Stockholm, Sweden
Monzr M Al Malki Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
Piyanuch Kongtim Stem Cell Transplant and Cellular Therapy, Thammasat University, Pathumthani, Thailand
Ephraim Fuchs Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Xiao-Jun Huang Peking University People's Hospital, Peking University Institute of Hematology, Beijing China
Franco Locatelli Department of Pediatric Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Sapienza, University of Rome, Italy
Franco Aversa Department of Medicine and Surgery, University of Parma, Parma, Italy
Luca Castagna Instituto Clinico Humanitas, Rozzano Milano, Italy
Andrea Bacigalupo Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Massimo Martelli University of Perugia, Sant'Andrea Delle Fratte, Perugia Italy
Didier Blaise Department of Hematology, Institut Paoli Calmettes, Marseille France
Patrick Ben Soussan Department of Clinical Psychology, Paoli-Calmettes Institute, Marseille, France
Yolande Arnault Institut Paoli-Calmette, département de psychologie clinique, Marseille, France
Rupert Handgretinger Department of Hematology and Oncology, University Children's Hospital Tübingen, Tübingen Germany
Denis-Claude Roy Division of Hematology and Medical Oncology, Hospital Maisonneuve-Rosemont, Montreal, QC, Canada
Paul O'Donnell Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Asad Bashey Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA
Scott Solomon Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA
Rizwan Romee Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Philippe Lewalle Hematology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Jorge Gayoso HGU Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
Michael Maschan Oncology and immunology, Dmitriy Rogachev National Medical Center of pediatric hematology, Moscow, Russia
Hillard M Lazarus Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
Karen Ballen Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA, USA
Sebastian Giebel Dept. of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland
Frederic Baron Laboratory of Hematology, University of Liège, Liège, Belgium
Fabio Ciceri Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano Italy
Jordi Esteve Hematology department, Hospital Clínic de Barcelona, Barcelona Spain
Norbert-Claude Gorin Service d'hématologie et thérapie cellulaire Centre international greffes APHP-EBMT-INCa Hospital, Saint Antoine Hospital, Paris France
Alexandros Spyridonidis Bone Marrow Transplantation Unit and CBMDP Donor Center, University Hospital of Patras, Patras, Greece
Christoph Schmid Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany
Stefan O Ciurea Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Arnon Nagler Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel and EBMT ALWP office, Saint Antoine Hospital, Paris, France
Mohamad Mohty Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorobonne University, and INSERM UMRs 938, Paris, France

Collapse

Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A, Solh MM. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor? Biol Blood Marrow Transplant 2019;25:2054-2060. [DOI: 10.1016/j.bbmt.2019.05.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 05/28/2019] [Accepted: 05/29/2019] [Indexed: 10/26/2022]

Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, Granata A, Maisano V, Pagliardini T, De Philippis C, Kogan M, Faucher C, Harbi S, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L. Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. Biol Blood Marrow Transplant 2019;25:1810-1817. [PMID: 31128326 DOI: 10.1016/j.bbmt.2019.05.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 05/09/2019] [Accepted: 05/17/2019] [Indexed: 10/26/2022]

Abstract

Haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) when a matched related or unrelated donor is not available. The role of graft source, either bone marrow (BM) or peripheral blood stem cells (PBSCs), in this setting has not been fully elucidated. We performed a retrospective study on 91 patients with HL to compare the outcome after BM (n = 53) or PBSC (n = 38) transplant. Eighty-nine patients engrafted with no difference between BM and PBSCs in terms of median time for neutrophil (20 versus 20 days, P = .405) and platelet (26 versus 26.5 days, P = .994) engraftment. With a median follow-up of 40.2 months, 100-day cumulative incidences of grades II to IV acute graft-versus host disease (GVHD) and grades II to IV acute GVHD were 24% and 4%, respectively. Graft source was not associated with a different risk of acute GVHD both by univariate and multivariate analyses. Consistently, 1-year cumulative incidence of chronic GVHD was 7% with no differences between the 2 graft types (P = .761). Two-year rates of overall survival (OS), progression-free survival (PFS), nonrelapse mortality, and GVHD/relapse-free survival (GRFS) were 67%, 58%, 20%, and 52%, respectively. By univariate analysis, pretransplant disease status was the main variable affecting all outcomes. By multivariate analysis, PBSCs resulted in a protective factor for OS (hazard ratio [HR], .29; P = .006), PFS (HR, .38; P = .001), and GRFS (HR, .44; P = .020). The other independent variables affecting the final outcome were pretransplant disease status and hematopoietic cell transplant-specific comorbidity index. In conclusion, when planning a haplo-SCT with PT-Cy for patients with poor-risk HL, graft type is an important variable to take into account when selecting the best available donor.

Collapse

Affiliation(s)

Jacopo Mariotti Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy.
Raynier Devillier Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Stefania Bramanti Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy
Laura Giordano Division of Biostatistics, Department of Oncology, Humanitas Clinical and Research Center, Rozzano, Italy
Barbara Sarina Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy
Sabine Furst Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Angela Granata Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Valerio Maisano Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Thomas Pagliardini Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Chiara De Philippis Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy
Maria Kogan Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy
Catherine Faucher Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Samia Harbi Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Christian Chabannon Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Centre de Recherche en Cancérologie de Marseille, Marseille, France
Carmelo Carlo-Stella Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
Reda Bouabdallah Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France
Armando Santoro Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy; Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy
Didier Blaise Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France
Luca Castagna Bone Marrow Transplant Unit, Humanitas Clinical and Research Center, Rozzano, Italy

Collapse

Allogeneic stem cell transplantation from unrelated donors in acute leukaemia. Curr Opin Oncol 2018;30:418-424. [DOI: 10.1097/cco.0000000000000485] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura R. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24:1828-1835. [PMID: 29753158 DOI: 10.1016/j.bbmt.2018.04.029] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 04/29/2018] [Indexed: 01/06/2023]

Affiliation(s)

Monzr M Al Malki Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California.
Nitya Nathwani Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Dongyun Yang Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, California
Saro Armenian Department of Population Sciences, City of Hope, Duarte, California
Sanjeet Dadwal Department of Infectious Disease, City of Hope, Duarte, California
Jaroslava Salman Department of Psychology & Psychiatry, City of Hope, Duarte, California
Sally Mokhtari Department of Clinical Translational Program Development, City of Hope, Duarte, California
Thai Cao Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Karamjeet Sandhu Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Michelle Rouse Department of Clinical Social Work, City of Hope, Duarte, California
Matthew Mei Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Haris Ali Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Pablo Parker Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Joseph Alvarnas Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Eileen Smith Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Margaret O Donnell Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Guido Marcucci Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California
David Snyder Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Auayporn Nademanee Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Stephen J Forman Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Anthony Stein Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California
Ryotaro Nakamura Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, California

Collapse

Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman SR, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu KC, Verneris MR, Krstajic D, Hicks B, Jones K, Lee SJ, Savage SA. No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 2018;53:383-391. [PMID: 29269807 PMCID: PMC5898974 DOI: 10.1038/s41409-017-0029-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 07/27/2017] [Accepted: 07/29/2017] [Indexed: 11/09/2022]

Affiliation(s)

Shahinaz M Gadalla Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Tao Wang Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA
David Loftus Telomere Diagnostics, Menlo Park, CA, USA
Lyssa Friedman
Casey Dagnall Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Michael Haagenson Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
Stephen R Spellman Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
Ljubomir Buturovic Clinical Persona, Inc., East Palo Alto, CA, USA
Marsha Blauwkamp Telomere Diagnostics, Menlo Park, CA, USA
Jason Shelton Telomere Diagnostics, Menlo Park, CA, USA
Katharina Fleischhauer Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
Katharine C Hsu Memorial Sloan Kettering Cancer Center, New York, NY, USA
Michael R Verneris Pediatric BMT, University of Colorado, Aurora, CO, USA
Damjan Krstajic Clinical Persona, Inc., East Palo Alto, CA, USA
Belynda Hicks Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Kristine Jones Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Stephanie J Lee Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Sharon A Savage Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA

Collapse

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. Bone Marrow Transplant 2018;53:576-583. [DOI: 10.1038/s41409-017-0076-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 11/20/2017] [Accepted: 12/03/2017] [Indexed: 11/08/2022]

Han LJ, Wang Y, Fan ZP, Huang F, Zhou J, Fu YW, Qu H, Xuan L, Xu N, Ye JY, Bian ZL, Song YP, Huang XJ, Liu QF. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol 2017;179:120-130. [PMID: 28737249 DOI: 10.1111/bjh.14854] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2017] [Accepted: 05/05/2017] [Indexed: 01/20/2023]

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biol Blood Marrow Transplant 2017;23:1736-1743. [PMID: 28688919 DOI: 10.1016/j.bbmt.2017.06.019] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 06/26/2017] [Indexed: 12/31/2022]

Abstract

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant cyclophosphamide (PTCy) protocols with haploidentical (haplo) donors have dramatically expanded the donor pool for patients requiring HCT. Initial studies were performed with bone marrow grafts, which require the donor to undergo anesthesia during harvest. However, the use of mobilized peripheral blood stem cells (PBSCs) may be desirable, especially with older donors. However, data on PBSC haplo-HCT in older adults are lacking. To characterize the impact of age on outcomes in haplo-HCT, we identified all adult patients undergoing haplo-HCT with PTCy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) at our institution from January 2009 to June 2016. Patients were grouped into 3 cohorts: Age 1 (≤55), Age 2 (55 to 65), and Age 3 (≥65). To characterize the impact of donor type on outcomes in older patients, we identified age- and disease risk index (DRI)-matched patient age ≥ 65 undergoing HLA-matched unrelated donor (MUD) HCT for AML or MDS during the same time frame. Patients were scored for disease risk and underlying comorbidities using the DRI and HCT-specific comorbidity index. Overall survival (OS) was analyzed using 3 different Cox proportional hazards models. We identified 112 haplo-HCT patients, 95 with AML and 17 with MDS. There were 61 patients in Age 1, 29 patients in Age 2, and 22 in Age 3. Median OS was 448, 397, and 147 days in Age 1, Age 2, and Age 3 patients (log-rank, P = .04). After adjusting for other risk factors, age ≥ 65 was associated with significantly worse OS after haplo-HCT (aHR, 2.16; 95% CI, 1.15 to 4.07). There was a trend toward increased relapse among older patients at 2 years (56%; 95% CI, 32% to 79%) versus Age 1 (41%; 95% CI, 28% to 54%) and Age 2 (31%; 95% CI, 12% to 50%) (P = .08). Among patients age ≥ 65, donor type (MUD versus haplo) did not impact OS (aHR, 1.03; 95% CI, .56 to 1.88) after adjusting for other risk factors. Prior allo-HCT (aHR, 4.95; 95% CI, 1.82 to 13.49) and myeloablative conditioning (aHR, 1.97; 95% CI, 1.04 to 3.73) were associated with inferior survival. Although age ≥ 65 was associated with inferior OS in our haplo-HCT cohort, no difference was seen in survival between MUD and haplo-HCT. Therefore, the use of haploidentical donors in older patients is a reasonable treatment option, especially if there is concern for clinical deterioration. A careful pretransplant evaluation and analysis of risks and benefits is warranted when offering this transplant modality to older adults, especially in patients with previous transplant or poor performance status. Strategies to reduce the risk of relapse and decrease nonrelapse mortality in older adults are areas of ongoing research, and prospective studies are needed.

Collapse

Kindwall-Keller TL, Ballen KK. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! Oncologist 2017;22:1125-1134. [PMID: 28546462 DOI: 10.1634/theoncologist.2017-0009] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 04/13/2017] [Indexed: 12/21/2022] Open

Abstract

Hematopoietic stem cell transplant (HSCT) is potentially curative for a wide variety of malignant diseases, including acute and leukemias, lymphoma, and myelodysplasia. Choice of a stem cell donor is dependent on donor availability, donor compatibility and health, recipient disease type, and recipient condition. Current sources of stem cell donation for HSCT are matched sibling donors (MSDs), matched unrelated donors (MUDs), 1-antigen mismatched unrelated donors (MMUDs), haploidentical donors (haplo), and umbilical cord blood (UCB) units. Historically, preferred donors for HSCT have been human leukocyte antigen (HLA)-matched sibling donors; however, only about 30% of U.S. patients will have a MSD available. The majority of patients referred for HSCT will require an alternative donor graft: MUD, MMUD, UCB, or haplo. The likelihood of finding a MUD varies depending on the ethnicity of the recipient. White Caucasians of European descent have the greatest chance of finding a MUD. Chances of finding a MUD are significantly less for African-American or Hispanic recipients due to HLA polymorphisms. Therefore, MMUD, UCB, and haplo donor graft sources expand the donor pool for recipients who do not have a MSD or MUD available. Given the variety of different donor stem cell sources available today, nearly every patient who needs an allogeneic HSCT has a potential donor in 2017. All transplant-eligible patients with hematologic malignancies should be evaluated by a transplant center to determine if HSCT is a viable treatment option for their underlying disease process.

IMPLICATIONS FOR PRACTICE

The goal of this review is to increase the awareness of oncology practitioners to the availability of alternative donor stem cell transplants for patients with hematologic malignancies. Despite new agents, stem cell transplant remains the only curative therapy for many patients with acute and chronic leukemia, myelodysplasia, and lymphoma. Given the variety of different donor stem cell sources available today, nearly every patient who needs an allogeneic stem cell transplant will have a donor.

Collapse

Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? Expert Rev Hematol 2017;10:479-492. [DOI: 10.1080/17474086.2017.1318054] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]